BD SurePath™ Pap Test

BD SurePath™ liquid-based Pap test

The BD SurePath™ liquid-based Pap test is an FDA approved thin-layer cell preparation process intended for use in the screening and detection of cervical cancer, pre-cancerous lesions, atypical cells and all other cytologic categories as defined by The Bethesda System for Reporting Cervical/Vaginal Cytologic Diagnoses.¹

FOCUS: Cervical Disease Detection Combined with Laboratory Efficiency.

BD SurePath™ liquid-based Pap test:

Can claim the greatest increase in disease detection of all Pap tests (64.4% increase in HSIL+ lesions detection² in comparison to the conventional Pap smear).

Significantly reduces Unsatisfactory and Satisfactory But Limited By (SBLB) cases³ for potentially fewer patient callbacks.

Removes most debris (e.g. blood, mucous, lubricant, inflammation) with maximum confidence in the result due to the proprietary BD SurePath™ Cell Enrichment process in your lab. Doctors are confident that their samples are handled properly in the lab.

FDA-approved for out-of-vial CT/GC testing using the BD ProbeTec™ CT/GC Q^x Amplified DNA Assays.

Try BD SurePath™ Pap test in your laboratory.

1	Kurman RJ, Solomon D (editors). The Bethesda System for Reporting Cervical/Vaginal Cytologic Diagnoses: Definitions, Criteria and Explanatory Notes for Terminology and Specimen Adequacy. New York, Springer Verlag, 1994.
2	BD PrepStain™ Slide Processor Product Insert. Direct-to-Vial study population.
3	BD PrepStain™ Slide Processor Product Insert. Split-sample study population.